Globalpharma and PrinceFarma Sign MoU to Advance Pharmaceutical Distribution in Angola

Collaboration will evaluate regulatory, commercial and distribution pathways for Globalpharma's portfolio in Angola

Dubai, United Arab Emirates, 16 Sep 2026 – Globalpharma, a wholly owned subsidiary of Dubai Investments and one of the UAE's leading pharmaceutical manufacturers, has signed a Memorandum of Understanding (MoU) with PrinceFarma, an Angola-based pharmaceutical distribution company, to advance pharmaceutical distribution in Angola.

The collaboration will focus on advancing regulatory alignment and establishing commercial and distribution frameworks for Globalpharma's portfolio in Angola, including the identification of priority therapeutic areas and structured pathways for market development.

The MoU was signed by Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries and Masharie and Board Director at Globalpharma and Aziz Rahemani, Managing Director of PrinceFarma Group.

Commenting on the collaboration, Dr Basem Albarahmeh, Chief Executive Officer of Globalpharma, said: *"This collaboration with PrinceFarma reflects Globalpharma's commitment to expanding access to high-quality healthcare solutions. As part of this collaboration, PrinceFarma will support the distribution of Globalpharma's pharmaceutical portfolio in Angola, complementing Globalpharma's plans to establish pharmaceutical manufacturing operations in DIP Angola."*

Aziz Rahemani, Managing Director of PrinceFarma Group, said: *"This partnership with Globalpharma is an important step towards improving access to high-quality medicines in Angola. By combining our local expertise with Globalpharma's strong pharmaceutical portfolio, we aim to better serve the country's healthcare needs and contribute to improving patient access to essential treatments."*

Globalpharma continues to strengthen its position as a regional pharmaceutical manufacturer through investments in research and development, manufacturing excellence and market development initiatives. The company remains focused on delivering quality pharmaceutical products while supporting sustainable long-term growth across its markets.

As Angola continues to invest in strengthening healthcare infrastructure and pharmaceutical supply chains, Globalpharma is focusing on leveraging opportunities for industry collaboration that supports improved healthcare delivery and local capacity building.

ENDS

About Globalpharma

Globalpharma is a wholly owned subsidiary of Dubai Investments PJSC. Established in 1998, Globalpharma is currently a market leader in key generic pharma segments with a strong regional footprint. Globalpharma started its operations in the UAE in 2003 and expanded its growth in 2008 with product line extensions and new product launches across 14 countries in the GCC and select African markets. Currently Globalpharma has two Manufacturing plants, A state of the art Beta-Lactam Penicillin Manufacturing plant providing the Amoxicillin & AmoxiClav brands in the larger MENA region. Additionally, catering to the Lifestyle disease segments, is a General Medicine Manufacturing Plant with a variety of Liquid & Oral Solid Dose capabilities. www.globalpharma.ae

About PrinceFarma

Prince Farma is a leading pharmaceutical company based in Angola, established in 2005. The company specializes in the production, distribution, sales, and marketing of pharmaceutical and healthcare products, serving a broad network across Angola. ISO 9001:2015 certified, Prince Farma is committed to providing quality healthcare products at accessible prices and works with international pharmaceutical partners to support the growing healthcare needs of the African market. https://www.princefarma.com/

About Dubai Investments PJSC

Dubai Investments is a publicly listed UAE based multi-asset investment Group, managing a diverse portfolio of businesses, generating sustainable financial returns to its shareholders. Established in 1995, Dubai Investments is one of the leading investments Group in the UAE, initiating new businesses and partnering with dynamic entities, creating strategic investment opportunities across the region. With 15,684 shareholders, a paid-up capital of Dhs. 4.25 billion and total assets worth more than AED 23.4 billion, the Group applies insight and experience to expand and be a reliable growth driver for businesses within sectors like real estate, manufacturing, healthcare, education, investments and services. The Group's diverse portfolio consists of wholly and partly owned companies and reflects the Company's continued focus on business diversification to drive growth in line with evolving industry trends. Focused on leveraging strengths with an interest in establishing existing and new business opportunities with a long-term, strategic and creative approach and with an emphasis on sustainable returns and capital growth, Dubai Investments collaborates on investment strategies meeting the changing needs of the economy and the societies in which it operates. Complementing the strategic objectives and creating value for stakeholders, the Group pursues growth through mergers and acquisitions and business expansions. To know more visit - www.dubaiinvestments.com

For more information contact:

Mohammed Al Shamsi
Manager – Investor Relations
Dubai Investments PJSC
Tel: +971 4 8122471
Email: mohammed.alshamsi@dubaiinvestments.com